Novavax (NVAX) Cash from Financing Activities (2010 - 2026)
Novavax (NVAX) posted quarterly Cash from Financing Activities of $37.7 million for Q1 2026, up 633.56% year-over-year from $5.1 million in Q1 2025, and up 670.49% quarter-over-quarter from -$6.6 million in Q4 2025.
Novavax (NVAX) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Novavax's Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $37.7 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 633.56% year-over-year to $37.7 million; the TTM figure through Mar 2026 stood at $72.5 million (down 70.73% YoY), while the FY2025 annual figure was $27.7 million, down 89.36% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $37.7 million, up from -$6.6 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $258.2 million in Q2 2024, with the low at -$354.4 million in Q1 2023.
- The 5-year median for Cash from Financing Activities is $5.9 million (2024), against an average of $38.6 million.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities tumbled 321.67% in 2023, then jumped 43854.64% in 2025.
- Novavax's Cash from Financing Activities stood at $191.4 million in 2022, then slumped by 47.56% to $100.4 million in 2023, then plunged by 103.41% to -$3.4 million in 2024, then slumped by 92.99% to -$6.6 million in 2025, then jumped by 670.49% to $37.7 million in 2026.
- Business Quant data shows NVAX's Cash from Financing Activities at $37.7 million in Q1 2026, -$6.6 million in Q4 2025, and $42.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Novavax | 1.33 Bn | 607.37 Mn | 42.45 Mn | 1.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.20 Mn |
| Jun 30, 2026 | 1.20 Mn |
| Mar 31, 2026 | 37.68 Mn |
| Mar 31, 2026 | 37.68 Mn |
| Dec 31, 2025 | -6.60 Mn |
| Dec 31, 2025 | -6.60 Mn |
| Sep 30, 2025 | 42.44 Mn |
| Sep 30, 2025 | 42.44 Mn |
| Jun 30, 2025 | -1.04 Mn |
| Jun 30, 2025 | -1.04 Mn |
| Mar 31, 2025 | -7.06 Mn |
| Mar 31, 2025 | -7.06 Mn |
| Dec 31, 2024 | -3.42 Mn |
| Dec 31, 2024 | -3.42 Mn |
| Sep 30, 2024 | -97,000.00 |
| Sep 30, 2024 | -97,000.00 |
| Jun 30, 2024 | 258.22 Mn |
| Jun 30, 2024 | 258.22 Mn |
| Mar 31, 2024 | 5.89 Mn |
| Mar 31, 2024 | 5.89 Mn |